Department of Medicine.
Department of Surgery, and.
Am J Respir Crit Care Med. 2021 Apr 1;203(7):893-905. doi: 10.1164/rccm.202008-3266OC.
Health outcomes of people with coronavirus disease (COVID-19) range from no symptoms to severe illness and death. Asthma, a common chronic lung disease, has been considered likely to increase the severity of COVID-19, although data addressing this hypothesis have been scarce until very recently. To review the epidemiologic literature related to asthma's potential role in COVID-19 severity. Studies were identified through the PubMed (MEDLINE) and medRxiv (preprint) databases using the search terms "asthma," "SARS-CoV-2" (severe acute respiratory syndrome coronavirus 2), and "COVID-19," and by cross-referencing citations in identified studies that were available in print or online before December 22, 2020. Asthma prevalence data were obtained from studies of people with COVID-19 and regional health statistics. We identified 150 studies worldwide that allowed us to compare the prevalence of asthma in patients with COVID-19 by region, disease severity, and mortality. The results of our analyses do not provide clear evidence of increased risk of COVID-19 diagnosis, hospitalization, severity, or mortality due to asthma. These findings could provide some reassurance to people with asthma regarding its potential to increase their risk of severe morbidity from COVID-19.
患有冠状病毒病 (COVID-19) 的人的健康结果从无症状到严重疾病和死亡不等。哮喘是一种常见的慢性肺部疾病，据认为可能会增加 COVID-19 的严重程度，尽管直到最近才获得有关该假说的数据。为了回顾哮喘在 COVID-19 严重程度中潜在作用的流行病学文献。通过 PubMed（MEDLINE）和 medRxiv（预印本）数据库使用“哮喘”、“SARS-CoV-2”（严重急性呼吸综合征冠状病毒 2）和“COVID-19”等搜索词，以及通过交叉引用在 2020 年 12 月 22 日之前可在印刷或在线获得的已确定研究中的参考文献，确定了研究。哮喘患病率数据来自 COVID-19 患者和区域卫生统计数据的研究。我们在全球范围内确定了 150 项研究，这些研究使我们能够按地区、疾病严重程度和死亡率比较 COVID-19 患者中哮喘的患病率。我们分析的结果并没有提供明确的证据表明哮喘会增加 COVID-19 诊断、住院、严重程度或死亡率的风险。这些发现可能会让哮喘患者对其因 COVID-19 而导致严重发病的风险产生一些安慰。
